X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SHASUN PHARMA NATCO PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 30.8 123.9 24.8% View Chart
P/BV x 23.3 8.5 273.1% View Chart
Dividend Yield % 0.5 0.2 210.6%  

Financials

 NATCO PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
SHASUN PHARMA
Mar-14
NATCO PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs87794 931.0%   
Low Rs42446 928.7%   
Sales per share (Unadj.) Rs223.4214.2 104.3%  
Earnings per share (Unadj.) Rs31.15.3 582.2%  
Cash flow per share (Unadj.) Rs40.315.8 254.6%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.81.4 53.7%  
Book value per share (Unadj.) Rs219.553.3 411.5%  
Shares outstanding (eoy) m33.0756.62 58.4%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.3 891.7%   
Avg P/E ratio x20.913.1 159.8%  
P/CF ratio (eoy) x16.14.4 365.4%  
Price / Book Value ratio x3.01.3 226.1%  
Dividend payout %16.118.7 85.9%   
Avg Mkt Cap Rs m21,5043,958 543.3%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1282,164 52.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,38912,127 60.9%  
Other income Rs m167229 72.9%   
Total revenues Rs m7,55612,356 61.2%   
Gross profit Rs m1,7931,009 177.7%  
Depreciation Rs m304594 51.3%   
Interest Rs m366415 88.2%   
Profit before tax Rs m1,290230 561.5%   
Minority Interest Rs m460-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309-73 -424.5%   
Profit after tax Rs m1,027302 340.1%  
Gross profit margin %24.38.3 291.7%  
Effective tax rate %23.9-31.7 -75.6%   
Net profit margin %13.92.5 558.1%  
BALANCE SHEET DATA
Current assets Rs m3,6816,884 53.5%   
Current liabilities Rs m3,1238,456 36.9%   
Net working cap to sales %7.6-13.0 -58.3%  
Current ratio x1.20.8 144.8%  
Inventory Days Days8962 145.2%  
Debtors Days Days59108 54.6%  
Net fixed assets Rs m7,6854,970 154.6%   
Share capital Rs m331113 291.9%   
"Free" reserves Rs m6,6702,875 232.0%   
Net worth Rs m7,2593,020 240.3%   
Long term debt Rs m9551,817 52.5%   
Total assets Rs m11,95713,347 89.6%  
Interest coverage x4.51.6 291.1%   
Debt to equity ratio x0.10.6 21.9%  
Sales to assets ratio x0.60.9 68.0%   
Return on assets %11.75.4 216.9%  
Return on equity %14.210.0 141.5%  
Return on capital %20.713.3 155.6%  
Exports to sales %39.446.4 84.9%   
Imports to sales %5.714.2 40.0%   
Exports (fob) Rs m2,9085,622 51.7%   
Imports (cif) Rs m4211,728 24.4%   
Fx inflow Rs m3,4455,843 59.0%   
Fx outflow Rs m7032,173 32.3%   
Net fx Rs m2,7433,669 74.7%   
CASH FLOW
From Operations Rs m1,440398 362.2%  
From Investments Rs m-1,089-1,635 66.6%  
From Financial Activity Rs m-3531,309 -27.0%  
Net Cashflow Rs m-171 -2.1%  

Share Holding

Indian Promoters % 52.0 39.2 132.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.6 217.8%  
FIIs % 16.6 17.6 94.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 39.6 65.7%  
Shareholders   25,395 20,750 122.4%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 16, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS